Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia

Walther, Sebastian; Mahlberg, Richard; Eichmann, Uta; Kunz, Dieter (2006). Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology, 185(4), pp. 524-8. Berlin: Springer-Verlag 10.1007/s00213-006-0343-1

Preview

Text 213_2006_Article_343.pdf - Published Version Available under License Publisher holds Copyright. Download (122kB) | Preview

RATIONALE: Nighttime agitation occurs frequently in patients with dementia and represents the number one burden on caregivers today. Current treatment options are few and limited due to substantial side effects. OBJECTIVES: The aim of the study was to measure the effect of the cannabinoid dronabinol on nocturnal motor activity. METHODS: In an open-label pilot study, six consecutive patients in the late stages of dementia and suffering from circadian and behavioral disturbances-five patients with Alzheimer's disease and one patient with vascular dementia-were treated with 2.5 mg dronabinol daily for 2 weeks. Motor activity was measured objectively using actigraphy. RESULTS: Compared to baseline, dronabinol led to a reduction in nocturnal motor activity (P=0.028). These findings were corroborated by improvements in Neuropsychiatric Inventory total score (P=0.027) as well as in subscores for agitation, aberrant motor, and nighttime behaviors (P<0.05). No side effects were observed. CONCLUSIONS: The study suggests that dronabinol was able to reduce nocturnal motor activity and agitation in severely demented patients. Thus, it appears that dronabinol may be a safe new treatment option for behavioral and circadian disturbances in dementia.

Interest & Impact

Downloads

704 since deposited on 04 Oct 2013
89 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item